LOGIN  |  REGISTER
C4 Therapeutics

Latest Diagnostics & Research News

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

July 9
Last Trade: 53.54 1.06 2.02

MADISON, Wis. / Jul 09, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal...Read more


Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet’s AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California

July 9
Last Trade: 55.32 0.06 0.11

Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelinesRegal Medical Group, Lakeside Community Healthcare and ADOC Medical Group are affiliates of one of Southern California’s largest health networks, which manages nearly 600,000 members from newborns to Medicare recipientsRegal Medical Group, Lakeside Community Healthcare and ADOC Medical...Read more


BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology

July 8
Last Trade: 0.54 -0.01 -1.82

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, today announces the advancement of a potential breakthrough targeted chemotherapy delivery platform designed to address a critical unmet need in precision oncology by localizing toxic chemotherapy drugs...Read more


Tempus AI Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. CHICAGO / Jul 08, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened...Read more


VolitionRx Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8
Last Trade: 0.72 0.05 6.77

HENDERSON, Nev., July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program,  tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The...Read more


OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress

MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech...Read more


Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

July 7
Last Trade: 158.48 -0.21 -0.13

AUSTIN, Texas / Jul 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples) with...Read more


BioNxt Solutions' Sublingual Cladribine Program for MS Ready for Next Phase

July 7
Last Trade: 0.54 -0.01 -1.82

VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC:XPHYF) (FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the receipt of the active pharmaceutical ingredient (API) for its lead product candidate, BNT23001. This proprietary sublingual thin-film formulation of cladribine is being developed for the treatment of multiple...Read more


QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

July 7
Last Trade: 30.82 1.61 5.51

New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO, July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has appointed two industry-leading executives to its leadership team....Read more


MDxHealth Appoints Michael Holder to Board of Directors and Announces Management Change

IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse...Read more


Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

July 1
Last Trade: 158.48 -0.21 -0.13

AUSTIN, Texas / Jul 01, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data...Read more


NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

June 30
Last Trade: 7.45 0.14 1.92

FORT MYERS, Fla. / Jun 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex...Read more


bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

SAN ANTONIO / Jun 26, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company’s recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property...Read more


DarioHealth and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

June 26
Last Trade: 0.71 0.0097 1.39

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in...Read more


Tempus AI: Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

June 25
Last Trade: 58.51 0.50 0.86

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of...Read more


OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed...Read more


bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

June 24
Last Trade: 0.34 0.04 14.30

Company research targets topical application for treatment of skin cancers SAN ANTONIO, Texas / Jun 24, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company’s novel composition...Read more


DarioHealth Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings

June 24
Last Trade: 0.71 0.0097 1.39

Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the...Read more


Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation

June 24
Last Trade: 0.75 0.02 2.05

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions,...Read more


Enzo Biochem To be Acquired by Battery Ventures in All-Cash Transaction

June 24
Last Trade: 0.31 0.00 0.00

Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that on June 23, 2025, following the market close, it entered into an Agreement and Plan of Merger (the “Merger Agreement”) to be acquired by Battery Ventures, a global,...Read more


NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

June 24
Last Trade: 7.45 0.14 1.92

FORT MYERS, Fla. / Jun 24, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life...Read more


Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

June 23
Last Trade: 99.27 2.12 2.18

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools...Read more


BioNxt Solutions Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets

June 23
Last Trade: 0.54 -0.01 -1.82

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT), is pleased to announce the launch of a feasibility study for the development of an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist currently marketed globally under the brand names Ozempic®, Rybelsus®, and Wegovy®. This initiative marks a significant step in evaluating...Read more


Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

June 23
Last Trade: 6.95 -0.01 -0.14

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his...Read more


LevelJump Healthcare Announces 2024 Financial Results

June 20
Last Trade: 0.05 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 20, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce its financial results for the year ended December 31, 2024. Financial and Operational Highlights Revenues were $17.7 million in 2024 compared to $12.6 million in revenues for 2023, a year over year revenue increase of 41%. Canadian Teleradiology Services, Inc., the Company's...Read more


Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization

BRANFORD, Conn. / Jun 19, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics." When: June 20, 2025, at 8...Read more


QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18
Last Trade: 47.85 0.32 0.67

GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays VENLO, Netherlands / Jun 18, 2025 / Business Wire / QIAGEN...Read more


Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

June 18
Last Trade: 0.11 -0.005 -4.55

Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland,...Read more


Bionano Genomics Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy

SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The   event highlighted the use of optical genome mapping (OGM) in genetic disease research, with numerous presentations and posters emphasizing its utility in detecting structural variants (SVs) associated with genetic diseases...Read more


Prenetics Global Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction

June 18
Last Trade: 8.11 -0.10 -1.22

Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million Prenetics simplifies investment thesis as company focuses on high-growth consumer health brands IM8, CircleDNA, and Europa Prenetics raised its FY2025 outlook to be US$80 – US$100 million from $73 – US$85 million, driven by the growth of IM8 CHARLOTTE, N.C., June 18, 2025 (GLOBE...Read more


Labcorp Launches Labcorp Whole Health Solutions to Support Holistic Care

June 18
Last Trade: 257.45 -0.42 -0.16

New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary care...Read more


Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

June 17
Last Trade: 347.78 1.05 0.30

News Summary Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security. Integration of Alliance™ iS HPLC System with Empower™ Software ensures user actions are identifiable and auditable. Minimizes common user errors by up to 40% and enhances audit readiness by providing end-to-end traceability and data integrity. BRUGES, Belgium and MILFORD, Mass., June 17,...Read more


Quantum-Si Customer to Showcase Protein Barcoding for Nucleic Acid–LNP Therapeutic Development at Festival of Genomics Boston

BRANFORD, Conn. / Jun 17, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, announces a featured talk at the upcoming Festival of Genomics & Biodata Boson, highlighting innovative advances in protein sequencing technology for drug development. Melissa Deck, Director of Platform at Liberate...Read more


HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025

SANTA CLARA, Calif. / Jun 17, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual...Read more


Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

June 16
Last Trade: 0.31 0.00 0.00

FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025. Financial Highlights The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life...Read more


Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

June 16
Last Trade: 19.76 0.30 1.54

Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance...Read more


ENDRA Life Sciences’ Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

June 16
Last Trade: 8.21 4.75 137.28

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation ANN ARBOR, Mich. / Jun 16, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to...Read more


Charles River Laboratories Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

June 16
Last Trade: 158.39 4.49 2.92

A solution for laboratories seeking to reduce single-use plastic waste WILMINGTON, Mass. / Jun 16, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe® bacterial endotoxin...Read more


QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15
Last Trade: 47.85 0.32 0.67

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports...Read more


LevelJump Healthcare to Acquire Two Alberta Diagnostic Imaging Clinics; Update on Year-End Reporting Documents

June 13
Last Trade: 0.05 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 13, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce that its subsidiary, Canadian Teleradiology Services ("CTS"), has signed a definitive agreement to acquire two diagnostic imaging clinics, also known as independent healthcare facilities ("IHFs"), from private Alberta vendors. The purchase price is $1.92 million cash which includes a $20,000...Read more


VolitionRx Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12
Last Trade: 0.72 0.05 6.77

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment...Read more


Tempus AI Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

June 12
Last Trade: 58.51 0.50 0.86

CHICAGO / Jun 12, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration...Read more


Agilent Technologies to Showcase New Products and Innovations at HPLC 2025

June 12
Last Trade: 121.01 1.76 1.48

SANTA CLARA, Calif. / Jun 12, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can...Read more


Prenetics Global Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

June 12
Last Trade: 8.11 -0.10 -1.22

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in March alone & provides Q2 revenue projections IM8 has more than 55,000 customers with 4.9 million servings delivered and counting Details of crypto strategy and Bitcoin adoption to be announced soon as part of...Read more


Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging...Read more


Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health

June 11
Last Trade: 0.08 0.00 0.00

AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet...Read more


IQVIA Launches New AI Agents for Life Sciences and Healthcare

June 11
Last Trade: 165.13 2.68 1.65

RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic...Read more


Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

June 10
Last Trade: 1.44 0.04 2.86

Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commencement of the next phase in its PancAlert project, a research initiative focused...Read more


Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program

NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share...Read more


Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17. To access a live webcast of the...Read more


Quantum-Si’s Single-Molecule Tech Enables Precise, Multiplexed Measurement of Nanobody Binding in a Single Assay

June 10
Last Trade: 1.83 0.00 0.00

Researchers at ESPCI Paris and Quantum-Si demonstrate scalable platform for parallel binding kinetics and sequencing in new preprint BRANFORD, Conn. / Jun 10, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, announces a new preprint from researchers at Quantum-Si and ESPCI Paris that...Read more


Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

June 10
Last Trade: 172.50 -1.47 -0.84

SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.  Under terms of the agreement, Quest will develop and...Read more


Izotropic Revises License Agreement with The Regents of the University of California

June 10
Last Trade: 0.26 0.02 6.12

License agreement enables U.S. FDA approval or foreign equivalent (CE mark) Amendment aligns with Company's timelines for IzoView product launch Agreement amendment fees of USD $85K payable in installments  Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company...Read more


New Study Published in ESMO Open Highlights Guardant Health Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

June 9
Last Trade: 50.82 1.28 2.58

LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse PALO ALTO, Calif. / Jun 09, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE